Key takeaways
- The hair-loss medicines FDA has approved include minoxidil (over the counter) and finasteride (prescription, men only); none of the approved hair-loss medicines we found is a peptide.
- In the US, a claim that a product will restore hair growth makes it a drug, and a 1989 rule requires an approved application for any non-prescription hair grower.
- The only placebo-controlled study of a GHK-Cu serum we found was in the eyebrows of 18 healthy adults, in 2026 conference proceedings.
- Biotinoyl tripeptide-1 and acetyl tetrapeptide-3 are built on the GHK sequence; the human studies of cosmetic hair peptides we found tested blends, some run by ingredient suppliers or product makers.
- Thymosin β4, the parent of TB-500, has hair studies in rats and mice; we found no human hair study of it on its own.
01Is any peptide approved for hair growth?
No peptide is among the hair-loss medicines we found approved in the US or the UK. Finasteride’s US label, for example, describes it as “a synthetic 4-azasteroid compound”.
- Minoxidil. In the US, Rogaine (NDA 019501, first approved 17 August 1988) is sold over the counter; the women’s label states its use as “to regrow hair on the scalp”. In the UK, Regaine foam is on the General Sales List, indicated “for the treatment of alopecia androgenetica in men”.
- Finasteride. Propecia (NDA 020788, approved 19 December 1997) is a prescription medicine whose US label is for “male pattern hair loss (androgenetic alopecia) in MEN ONLY”. In the UK it is a prescription-only medicine.
- For severe alopecia areata, an autoimmune form of hair loss, FDA has approved kinase inhibitors, including ritlecitinib (Litfulo, 2023) and deuruxolitinib (Leqselvi, 2024).
In Australia, the Poisons Standard (October 2026) lists minoxidil in Schedule 2 (pharmacy medicine) for skin preparations up to a set strength and in Schedule 4 (prescription only) otherwise, and finasteride in Schedule 4. A schedule entry is not an approval of any product.
Why cosmetics can’t claim it. FDA lists claims that products “will restore hair growth” among claims that make a product a drug, “even if the product is marketed as if it were a cosmetic”. A 1989 rule adds that any non-prescription product “labeled, represented, or promoted for external use as a hair grower or for hair loss prevention” is a new drug that needs an approved application, and records “a lack of adequate data to establish general recognition of the safety and effectiveness” of any ingredient for that use. In the UK, the MHRA’s guidance on what counts as a medicine summarises a 1991 European Court ruling on minoxidil sold as a cosmetic: a product is a medicine if it is given “with a view to … restoring, correcting or modifying” physiological functions.
02Which peptides have hair studies, and who ran them?
Peptides tested in hair studies, dated 18 November 2026. “Who ran it” separates studies by product makers and ingredient suppliers from independent ones. Tiers follow our evidence grades.
| Peptide | What it is | Highest-tier hair study we found | Who ran it | Tier | What we don’t know |
|---|---|---|---|---|---|
| GHK-Cu (copper tripeptide-1) | Copper complex of the tripeptide glycyl-histidyl-lysine (GHK) | Bo et al., 2026: randomised, double-blind, split-face; a GHK-Cu serum on one eyebrow and a placebo serum on the other; 18 healthy adults aged 18 to 40; 12 weeks; conference proceedings | Researchers at a university in Thailand | T1, small, eyebrows only | Whether GHK-Cu alone changes scalp hair in people with hair loss: we found no controlled trial of it |
| Acetyl tetrapeptide-3 | Acetyl-Lys-Gly-His-Lys amide, a four-amino-acid peptide containing the GHK sequence (PubChem) | Lueangarun and Panchaprateep, 2020: randomised, triple-blind; a lotion combining it with biochanin A and ginseng extracts against minoxidil solution; 32 adults with pattern hair loss; 24 weeks | Independent: no funding, no conflicts declared | T1, small, combination only | Its effect separate from the other ingredients; there was no placebo arm |
| Thymosin β4 (parent of TB-500) | A 43-amino-acid protein | Philp et al., 2004: rats and mice, hair growth measured, and hair-follicle stem cells in culture. Gao et al., 2015: mice engineered to make more of it, or none | Philp 2004: a National Institutes of Health laboratory (US). Gao 2015: a university research centre in China | T3 / T4 | Anything in people: the only human hair study we found used it as one of several actives |
03What have studies of GHK-Cu and cosmetic hair peptides measured?
GHK-Cu. Our page on copper peptides and hair lists every hair study of a copper peptide we found. In short: the only placebo-controlled study of a GHK-Cu serum we found was in the eyebrows of 18 healthy adults, published in conference proceedings in 2026. The other human studies used GHK without copper, combined a copper peptide with other actives or drugs, or had no control group; the animal and lab work used other copper peptides or is known only by its title. A 2026 evidence map of GHK-Cu in Pharmaceutics found its clinical evidence “remains sparse and does not meet contemporary active-entity quality standards”.
GHK-based cosmetic peptides. Two cosmetic peptides are built on the same sequence. Biotinoyl tripeptide-1 is biotin joined to GHK, and acetyl tetrapeptide-3 is acetyl-Lys-Gly-His-Lys amide (PubChem). Neither contains copper. The human studies of cosmetic hair peptides we found tested blends:
A 2020 randomised, triple-blind trial in Thailand compared a lotion of acetyl tetrapeptide-3, biochanin A and ginseng extracts with minoxidil solution in 32 adults for 24 weeks, with no placebo group. The authors declared no funding and no conflicts.
Two clinic studies combined platelet-rich plasma (PRP) sessions with Procapil, a commercial blend: a 2023 randomised trial in 54 men in India, whose paper describes Procapil as oleanolic acid, apigenin and “the peptide glycine-histidine-lysine”, and a 2024 quasi-experimental study of 160 patients in Pakistan. We could not confirm from a primary source which peptide form the blend contains.
A 2013 placebo-controlled study of 30 volunteers over 4 months came from the research department of an ingredient supplier and tested its red clover and peptide ingredient; the abstract does not name the peptide.
A 2021 open (unblinded) randomised study of 100 women with acute telogen effluvium, a temporary shedding after a trigger, tested a lotion with creatine, acetyl tetrapeptide-2 and B vitamins against a mild shampoo alone; all four authors list Pierre Fabre affiliations, and PubMed lists Pierre Fabre Dermo-Cosmétique, a cosmetics company, as its funder.
With several active ingredients in each product, these studies cannot show what any one peptide does. A 2026 systematic review in the Journal of Drugs in Dermatology included 14 clinical trials of peptide-containing products for hair loss, searched to November 2025, and its abstract discusses formulations rather than single peptides; we could not read its full text to see which trials used which peptide.
04What has thymosin β4 hair research measured, and in which models?
Animal and lab work (T3, T4). Thymosin β4 is a 43-amino-acid protein; TB-500 is a fragment of it. In 2004, researchers studied thymosin β4 in rats and mice, measuring hair growth, and measured in culture how hair-follicle stem cells from rats migrated and changed in its presence. In 2015, researchers compared mice engineered to make more thymosin β4 in the skin with mice lacking it, measuring hair regrowth after hair removal, the number of hair shafts and follicle patterns. We describe what these studies measured, not their findings, because they are animal studies of the parent of a compound sold online as TB-500.
In people. We found no human hair study of thymosin β4 or TB-500 on its own, and no registered one (PubMed and ClinicalTrials.gov, 18 Nov 2026). The one human hair study we found that included it was a 2018 single-arm study of 1,000 patients given a clinic formulation of several growth factors that also contained copper tripeptide-1, so it cannot show anything about thymosin β4 alone. More: the thymosin β4 guide.
05What we don’t know about peptides and hair growth
- Whether GHK-Cu or any cosmetic peptide on its own changes scalp hair in people with hair loss. The controlled human studies we found tested blends, GHK joined to another molecule without copper, or eyebrows in healthy adults.
- How these peptides compare with the approved medicines. The trial against minoxidil described above had 32 people, used a blend, and had no placebo group.
- How much of a peptide in a scalp product reaches the hair follicle. None of the human studies above reports measuring it.
- Whether the rodent findings for thymosin β4 apply to people. No human study has tested it alone for hair.
- Long-term effects. The controlled studies above lasted 6 months or less.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not medical or legal advice.